Detecting the earliest possible signs of type 2 diabetes
Detecting the earliest possible signs of type 2 diabetes
Randox Laboratories is this month driving awareness of diabetes and the need for early and accurate diagnosis to enable patients to take preventive action before the condition worsens.
Diabetes UK have stated that diabetes is the fastest growing health threat of our times and an urgent public health issue. Statistics show that since 1996, the number of people living with diabetes has more than doubled. It has been estimated that there are 1.1 million people living with diabetes in the UK that have yet to be diagnosed, including 84,836 people in Northern Ireland.
According to Diabetes UK around 700 people a day are diagnosed with diabetes, which equates to one person every two minutes. If nothing changes, it is estimated that diabetes will affect one in ten people by 2040. This will raise diabetes prevalence from 415 million to 642 million by 2040. With current treatment taking up almost 9% of the annual NHS budget – roughly £8.8bn a year – the implications for future healthcare budgets are clear if this dangerous trend persists.
The good news however, is that recent research has found that type 2 diabetes is preventable through lifestyle changes. The NHS recently released the UK’s National Diabetes Prevention Programme which is aimed at tackling the increasing growing threat of diabetes.
However, following a warning raised by an Oxford University study, which looked into efforts of this Prevention Programme, it was found that it is unlikely to have much impact because the blood tests used were inaccurate at detecting pre-diabetes – the stage at which diabetes is reversible.
The blood tests used in the National Diabetes Prevention Programme were only effective at detecting diabetes at a stage when damage had already been done.
At Randox, we have developed a number of tests that can help detect the earliest possible signs of diabetes, often before symptoms have even manifested – including a pioneering test for the hormone Adiponectin.
Assessing Adiponectin levels allows doctors to calculate a patient’s levels of visceral fat – a dangerous, internal fat stored around organs. This deep fat, which is not visible to the naked eye, is linked to health problems including Type-2 diabetes.
Low levels of adiponectin equate to high levels of visceral fat which can be combated by improving your diet, exercise habits and even stress levels. Given that 70% of Type-2 diabetes can be prevented by lifestyle changes, there is strong correlation that by detecting low levels of Adiponectin and taking corrective and preventive action, it could result in a decrease in the numbers of people who develop the life-altering condition.
In addition to a test for the Adiponectin biomarker, Randox Biosciences have created a Metabolic Syndrome Array that measures 12 markers associated with metabolic syndrome and cardiovascular disease. Metabolic Syndrome is a is a group of cardiovascular risk factors that affects over 20% of adults and results in a person being three times more likely to have a stroke or heart attack, and five times more likely to develop diabetes.
Ultimately, we would like to see all medical professionals who are at the forefront of patient care armed with the most accurate diagnostic tools available. Updating traditional practice may not be easy but we believe it is imperative to do so, if we are to effectively challenge this global epidemic.
Randox remains focused on providing early diagnoses and preventing illnesses by providing innovative diagnostics tests that will continue to revolutionise the healthcare landscape.
For further information, please contact Randox PR by emailing randoxpr@randox.com or phoning 028 9442 2413.
Randox Teoranta set to host Science, Engineering and Manufacturing Career Open Day on Christmas Eve
Do you have a flair for science? Are you an electronic, mechanical or software engineering expert? Or, perhaps, you are a mastermind of manufacturing know-how. There are world-leading careers on offer for world-leading candidates at Randox Teoranta in Dungloe this December.
That’s the message that global diagnostics firm Randox Teoranta wants to send to students, graduates and experienced professionals alike as it opens its doors to the public once again on Monday 24th December 2018.
Held from 9am to 12noon, the morning is an opportunity for those interested in science, engineering, software development and manufacturing roles in Donegal to have a tour of the state-of-the-art facility and chat with Randox Teoranta staff members about the careers on offer.
Randox Teoranta is particularly passionate about attracting back those who have left Ireland to find careers further afield due to lack of opportunities in their particular vocations. Dream careers in science, engineering and manufacturing are available on the doorstep in Dungloe.
Dr. Ciaran Richardson, Head of Research & Development at Randox Teoranta, commented;
“At Randox Teoranta, we’re constantly pushing the boundaries of healthcare and diagnostic capabilities, allowing us to offer world-class career opportunities in the heart of Donegal.
“Our scientists are working on a range of research projects which will lead to quicker diagnoses of conditions such as stroke, gastrointestinal disorders and chronic kidney disease. In 2016, our scientists even developed a pioneering new test to determine a patient’s risk of developing Alzheimer’s disease.
“There are also opportunities for software developers, electronic & embedded systems engineers, validation and mechanical engineers as our technology continues to advance to accommode our scientific breakthroughs.
“Our manufacturing department also boasts a number of competitive roles which are essential to Randox Teoranta’s continuation as a world leader in healthcare diagnostics and associated technology.
“There are fantastic career opportunities here in one of the most beautiful parts of the world – and the quality of life is second-to-none.”
There are a wide variety of career opportunities available at Randox Teoranta. From placement opportunities for college and university students to graduate roles in a variety of fields, young scientists and engineers have the opportunity to get their ‘big break’ on the career ladder with a globally-recognised company.
There are also opportunities for experienced and driven individuals looking for a smart career move. Randox Teoranta offer competitive salaries, career progression, personal development and the opportunity to work in a cutting-edge company paving the way in ground-breaking global health diagnostics.
Healthcare shouldn’t be one-size-fits-all. Neither should your career.
Randox Teoranta’s Open Morning will take place on Monday 24th December 2018 from 9:00 until 12:00 at Randox Teoranta, Meenmore, Dungloe, Co. Donegal.
Students, graduates and experienced professionals are welcome to visit along with their family and friends. Potential candidates are welcome to bring their CV on the day or email it to recruitment@randoxteoranta.com.
Booking is not required, however, more information, including directions, can be found by searching Randox at www.eventbrite.ie.
More information about the open day can also be found by contacting +353 7495 22600 or emailing RandoxPR@randox.com.
Randox Biosciences and Familial Hypercholesterolemia (FH)
Familial Hypercholesterolemia (FH) is a genetic disorder where the child is born with extremely high cholesterol levels. FH can trace back through several generations. Cholesterol is vital for the normal function of the human body therefore, it is important to ensure the cholesterol levels don’t get too high because it can result in early onset cardiovascular disease. 1
The FH Foundation states an interesting fact that 1 in 250 people worldwide have FH and over 90% of these people have not been properly diagnosed 2. Majority of these people won’t know they have FH disease until they have a heart attack!
However, there are no clear symptoms if someone has FH until it is too late and the damage has been done. The warning signs include the following:1
- Swollen tendons/fatty lumps on the knuckles of your hands, at the back of your ankles and knees
- Cholesterol deposits around the eye-lids (looks like pale and yellowish patches)
- Gray-white cholesterol deposits around the corneas
A study in 2008 by the British Heart Foundation found that people with FH who are diagnosed and treated before they develop heart disease live as long people who don’t have FH 4. This theory emphasis the importance of getting early diagnosis to prevent long-term problems. Treatment to prevent cardiovascular disease involves taking medication prescribed by the doctor and making lifestyle changes including; modifying diet, increasing exercise, quit smoking, decrease drinking alcohol and ensure the patient gets regular sleep.
Randox offers the Familial Hypercholesterolemia (FH) Arrays I & II to help encourage early diagnosis with rapid turnaround time allowing results to be reported within days compared to NHS waiting lists which can be substantially longer. The two arrays are rapid, simple and accurate which enables the simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes. The mutational status can be determined rapidly from a single test, with a reduced need for confirmatory testing with NGS. The genetic analysis for FH mutations allows for more accurate diagnosis compared to lipid profiling.
Randox can help using the award-winning Biochip Analyser to achieve early and appropriate treatment for those with FH resulting those to adopt a healthier lifestyle and taking cholesterol-lowering medication, risk of heart disease to live a longer and healthy life!
Familial Hypercholesterolemia (FH) Arrays I & II:
- LDLR – 38 mutations
- APOB – 1 mutation
- PCSK9 – 1 mutation
To find out more about the products that we offer email us info@randoxbiosciences.com
Reference:
https://www.healthline.com/health/familial-hypercholesterolemia#symptoms
The world’s most extensive Drugs of Abuse Test Menu
Randox Toxicology offers the most comprehensive Drugs of Abuse (DoA) test menu across multiple forensic matrices. Our level of expertise in toxicology research and development allows us to adapt quickly to the ever-changing market influences and develop assays for current and novel drugs trends. Excellent assay precision and performance eliminates false reporting, therefore reducing unnecessary confirmatory tests and time lost in the laboratory as a result. Our Biochip Arrays offer CVs typically less than 10%, producing an accurate drug profile to ensure confidence in results.
| DoA II | ||
| Buprenorphine | Ketamine | Oxycodone I |
| Creatinine | LSD | Oxycodone II |
| Fentanyl | MDMA | Propoxyphene |
| Generic Opioids | Methaqualone | – |
The Evidence Series of immunoassay analysers are powered by Biochip Array Technology and combine the latest technological advances for drug residue detection using immunoassay principles. The Drugs of Abuse II panel is available for both the Evidence and the Evidence Investigator analysers. The Evidence has a throughput of 90 samples per hour, testing up to 44 tests per sample. The Evidence is a fully automated batch immunoanalyser, allowing for 3960 tests per hour, while the Evidence Investigator is a semi-automated, bench top analyser with testing capabilities of 2376 tests in 70 minutes.
To find out more about our Biochip Array Technology and our Evidence Series analysers, visit www.randoxtoxicology.com, or email us at info@randoxtoxicology.com
Tackling Worldwide Drugs of Abuse
Throughout November, we’ve been highlighting how the Randox clinical teams – Randox Rx series, Randox Reagents and Randox QC – are aiding the fight against drugs of abuse.
Drugs of Abuse are a growing problem worldwide and represent a significant burden to healthcare systems as well as creating problems in an individual’s lifestyle. It has been estimated by the WHO (World Health Organisation) that 31 million people globally suffer from drug use disorders and 3.3 million deaths each year are linked to the abuse of both drugs and alcohol.
The abuse of drugs is one of the most pressing issues in the United States of America. Drug abuse not only affects the individual, but also can have far-reaching consequences that affect family, employment, personal health, health care systems, local communities, and society as a whole.
- Misuse of illicit drugs affects society through secondary costs incurred such as crime, reduced productivity at work, and health care expenses.
- Substance abuse costs the US health care system about $11 billion, with overall costs reaching $193 billion.
- Substance abuse and addiction also affects other areas of life and can cause broken families, destroyed careers, death due to negligence or accident, domestic violence, physical abuse and child abuse.
- Drug abuse and addiction changes the chemistry of your brain. The longer you use your drug of choice, the more damage is caused and it becomes more difficult to return to ‘normal’ during drug rehabilitation.
- In 2013, 22.7 million Americans needed treatment for a substance use disorder – almost 9% of the population over the age of 12. Only about 2.5 million received treatment as a specialist facility with 20% of admissions for opiate addication treatment and 17% for the treatment of marijuana abuse.
To find out more about how Randox is helping in the fight against Drugs of Abuse, please visit https://www.randox.com/drugs-of-abuse/ or for more information about Randox RX, Randox Reagents or Randox QC, please email marketing@randox.com.
We Are Randox | Match Report from FinTrU Ulster GAA Inter-Firms Junior Menās Competition
On Saturday 17th November 2018, hot on the heels of the Randox GAA Ladies team’s glorious competition début, our Men’s team took to the field at the Tyrone GAA Centre of Excellence, to compete in the Junior Men’s category of the FinTrU Ulster GAA Football Inter-Firms competition.
With our Ladies team having successfully reached the Semi-Finals of the competition the week prior, the pressure was on!
The two Randox Men’s teams were pooled in separate groups with strong opposition in both. Randox Team One faced a tough task with FinTru, Citi and South West College, whilst the second Randox Team were pitted against the GAA Store, Premier Electric and Belfast Lawyers.
Our Randox teams battled hard during this group stage and thanks to a creative team effort as well as some fantastic individual performances, they both made it to the knockout stages of the competition and into the quarter finals. Unfortunately though, the effort put in to make it out of the group stages had claimed a few key players to injury, which left the remaining men with a near impossible task ahead of them in the next stage of the competition
Team One was drawn against FinTru and Team Two against Belfast Lawyers. Regrettably, on the day both teams came out on the wrong side of the results in very competitive games against very experienced and seasoned teams.
John James Fallon, Randox Electrical Engineer and GAA Bainisteoir / Coach, commented;
“As newly-formed teams, who prior to the Inter-Firms competition had never played together before, both the men and ladies should be extremely proud. Fielding players who ranged from experienced to novice, and with only 5 weeks training, to have reached the quarter-finals and semi-finals of our respective categories has been exceptional.
“On behalf of the organising committee I would like to say thank you to Randox and Dr FitzGerald for their assistance in getting the team started, and to St James GAC Aldergrove for the use of their facilities and equipment over the course of the training sessions, as without their help this would not have been possible. Finally, a huge thank you has to go to the participants themselves, as without you there is no Randox GAA club. I’m looking forward to our next season together already.
“This is just the beginning.”
On behalf of everyone at Randox we would like to wish both our Ladies GAA Team and our two Men’s GAA teams a massive congratulations on their impressive performances at the FinTrU Ulster GAA Football Inter-Firms competition.
Their commitment, perseverance and teamwork has been truly inspiring and we are very proud of how they came together to form three very capable and motivated GAA teams. Well done!
For further information on our Randox GAA teams, please email johnjames.fallon@randox.com
Significant drop in veterinary antibiotics sales across Europe
Randox Food Diagnostics recently reported that the European Parliament has banned the use of antibiotics that are important for human medicine use on animals, and is prohibiting any antimicrobials in livestock without a vet prescription. The new legislation, that is to become law by 2022, states that antimicrobials cannot be used to improve performance or compensate for poor animal conditions.
The European Medicines Agency (EMA) have now documented a significant drop in overall veterinary antibiotic sales across Europe. The EMA recognise that the reduction highlights the efforts made by the European Union (EU) and various stakeholders, promoting prudent use of antibiotics in the animal sector and its positive impact. The reduction of antibiotic use in food-producing animals is a key pillar to the EUs One Health Action Plan against Antimicrobial Resistance (AMR), according to a report conducted by the University of Minnesota.
30 countries in total submitted data between 2011 and 2016. German antibiotic sales dropped by 58%. However, whilst the majority of countries saw a drop in sales, six countries reported an increase of more than 5%. Germany’s implementation of an antibiotic minimising programme has helped the country to minimise antibiotic use, by requiring farmers raising cattle, pigs, chickens, or turkeys to report the frequency of antibiotic treatment on their farm every 6 months. If animal treatment frequency is above the median of all farms, operators must evaluate their usage with a veterinarian.
This major step forward in public health has a direct impact on the environment and food. Randox Food Diagnostics recognise the importance of improving the global food safety chain, and continue to transform the landscape by developing high quality revolutionary screening products. Our reliable and economic testing methods enable the user to detect multiple drug and toxin residues from a single sample, including antimicrobials, growth promoting compounds, synthetic steroids, anthelmintics and coccidiostats. With an expanding range of 37 ELISAs, 21 multiplex screening arrays and 20 enzymatic/colourmetric reagents, our trusted solutions ensure that better science means safer food.
For any questions, email us directly at: info@randoxfooddiagnostics.com
Reporting, Expert Witness and Medical Review Services from RTS
RTS Reporting Services
At Randox Testing Services we provide a number of reporting options to our customers, including expert witness reports and medical reviews to add clarity and expert examination to results.
Expert Witness Services
An Expert Witness Report is an interpretation of the results of a drug or alcohol test. It provides a detailed explanation of whether or not substances tested for were detected as well as information regarding chain of custody compliance and testing procedures.
As trusted industry experts Randox Testing Services staff are trained to act as Expert Witnesses in legal cases involving drug and alcohol testing. Our experienced team of Reporting Scientists have undergone extensive Expert Witness training to provide professional witness statements or fully written reports for use as evidence in a court of law or industrial tribunals.
Where required a Senior Toxicologist from Randox Testing Services can attend legal proceedings in person to provide expert witness testimony.
Medical Review Services
Our medical review service offers independent and expert examination of positive results under medical confidentiality.
A positive result from a drug and alcohol analysis is a cause for concern. However, there are some cases when there is a legitimate medical reason for the result. Our medical review service allows for the independent and confidential review of the result to determine the cause of a positive result, for example, if an employee is taking prescription medication.
The Medical Review Officer (MRO) assesses a positive result in the light of the donor’s medical background to determine if there is a legitimate medical reason for the result. The MRO helps protect both the rights of the employee being tested and the employer requiring the testing.
Randox Testing Services
At Randox Testing Services we offer customers access to our expertise through providing various reporting options to customers. These reporting services can be utilised in cases where extra clarity or examination is needed to investigate the outcome of a drugs test. These reports are utilised by workplaces as well as those operating within the medico-legal sector.
For more information on our training, education and reporting services, click here.
If you would like to find out more about our drug and alcohol testing programs, contact us today to speak to one of our experience business development executives.
Web: www.randoxtestingservices.com
Email: testingservices@randox.com
Phone: +44 (0) 28 9445 1011
We Are Randox | Software Developer Scott McPeake on life in the Randox IT department
Have you heard about our IT Open Evening on Tuesday 20th November? We’re offering those interested in Software Development, Information Security, Web Design and IT Support the opportunity to have a look around our state-of-the-art IT facilities at the Randox Science Park.
But as a company known throughout the world for its high-quality health diagnostic products, you may have been surprised to hear that we have such wide-ranging roles available in Information Technology.
“Randox? Isn’t that just for scientists?” we hear you say.
We turned to Randox IT Software Developer Scott McPeake for the answer. This is what he said.
“I imagine if you were to ask my friends from my Computer Science course at university, if they previously knew that Randox offers jobs in IT, they would say no.
But really, it’s not surprising when you think about it. Technology underpins everything we do in life. Everything is moving digital, and everything digital involves software in some shape or form.
Even jobs which you assume are predominantly tech-free – let’s say for example, a bus driver – use technology every day. A bus driver relies on technology to administer tickets and to plan their travel routes. It truly is everywhere and it’s only going to expand more.
Without an innovative IT department, Randox wouldn’t be the successful and reputable company it is today. If there was no IT team, there would be no lab equipment, no websites, no apps. Even organisations who don’t specialise in IT still have it as a core function of the company.
In the Software Development team, in particular, we design and develop the software used in laboratories to compare results from instruments and samples against other laboratories, to see how these results compare.
It’s important work, as all our scientists rely on us to be able to do their work in providing blood test results to patients across the world. Our software needs to be operating perfectly to ensure people are getting the correct results and therefore the correct diagnosis. And that’s what makes Randox so reputable.
Access to technologies
Being part of a company that is so well established and successful also means that we get exposed to the latest innovations. With IT influencing so much of what we do here, we’re at the forefront of all projects and developments, and are given access to the most up-to-date technologies to make sure we’re providing the best possible products and user experience for our customers, and can stay head of our competitors.
We’re able therefore to bring to management our ideas about what new software we would like to try, to suggest how it would improve our work. So new software is coming in all the time. I’m currently working with MVC architecture which is a key software framework used widely across the world. It’s definitely something good to get experience in, as is typescript, which although not used as much, is really interesting, and I’ve certainly enjoyed the opportunity to try something new.
We also work with C# and javascript which are popular, up-to-date products. So whilst the industry of health diagnostics is rather niche, we have the opportunity to use design patterns that are used by most companies, in most industries, to realise our aim of advancing global healthcare.
And of course, working in Randox, we also get the opportunity to learn about the science of diagnostics, and in particular the machines on which we’re implementing our software designs, which carry out blood testing in hospitals and laboratories. It’s good to challenge yourself to learn something new.
Teamwork and collaboration
The chance to expand your knowledge and improve your skills repertoire is probably one of my favourite things about working here at Randox. Everyone works really collaboratively and we help each other out when we need it. So if you don’t know something, no one is going to chastise you. Asking for help and advice is actively encouraged because we each have our own strengths and weaknesses and we can help each other to be a better team. Everyone in the Randox IT team is really willing to help and makes time for you if you need it.
I remember on my first day here I was really nervous and I arrived at the door unable to get in because it was locked. Someone in the team immediately came to the door, asked me if I was new and welcomed me in to the building. That instantly set the tone. Everyone was really welcoming, friendly and professional.
And this ability to work together is so crucial. Most days we will be working on the same site but perhaps on different pages so we have to talk to each other to make sure my page doesn’t break theirs and vice versa. Quite often we’ll design the layout of the software collaboratively, and most days we’ll have a morning meeting to discuss our progress.
If we’re creating something new, we’ll draw up the design based on user requirements and create the software to those designs. Or if an existing site doesn’t work properly, we’ll write up the problem, how to solve it, and then push it up to the production server to fix the bugs.
Fundamental skills
So communication is fundamental, as is problem solving. Being able to keep calm under pressure is also an inherent skill for programming. Deadlines happen; they’re a real thing. You can’t take all day to do something. But it keeps things challenging for us, which is vital, as you don’t want to put your brain to sleep. The work is challenging but solvable, and as I said, you have the team there to help you out and support you.
We all get on really well and the more experienced software developers in the team have been such great mentors to me. If you’re interested in working in IT I would certainly recommend coming along to our IT Open Evening on Tuesday 20th November so that you can meet all of us and have the opportunity to take a tour of our brand-new facilities in the Randox Science Park.
Working in Antrim
The site is really spacious, modern, and easy to get to. For me, coming from Coleraine, I’m just able to get the train to the Antrim station, which is right beside the bus station aswell.
And Antrim has everything you could need. Shops, supermarkets, nice affordable places to live, and plenty of cafés and restaurants. Sometimes we’ll head out as a team in to Antrim for lunch or dinner together, or if we fancy Belfast, it’s just a short journey on the train.
So if you’re interested in a dynamic career in software development, take the trip to Antrim to find out a bit more about what Randox has to offer during our Open Evening on 20th November.
You might not have thought of Randox as a software house but we’re here and we’re working hard to improve healthcare globally!”
To attend the Randox IT Open Evening on Tuesday 20th November, register for tickets on EventBrite by clicking here.
For further information please contact the Randox PR team by emailing randoxpr@randox.com or phoning 028 9442 2413
World Diabetes Day: The Biggest Burden on the NHS
Diabetes
Approximately 400,000 people in the UK are living with type 1 diabetes, with over 29,000 being children and young people [1]. Type 1 diabetes affects 96% of all children with diabetes in England and Wales, with incidences increasing by approximately 4% each year.
Globally, the UK has the fifth highest rate of type 1 diabetes diagnosis in children (aged up to 14) with 85% of these children having no family history of the condition. Whilst the condition isn’t fatal and can be managed, it cannot be cured. Type 1 diabetes increases the risk of developing other health problems such as heart disease, stroke, foot and circulation problems, sight problems including blindness, nerve damage and kidney problems. However, many of these related conditions are preventable and it is recommended to stabilise blood sugar levels, attend diabetes appointments regularly and complete a diabetes course to educate patients and family members and prevent the risk of further help complications[2].
Diabetes in children
Children under five are at the highest risk of developing diabetic ketoacidosis due to a late diagnosis and it is also thought to be due to of lack of public knowledge of the signs and symptoms attributed to type 1 diabetes. Such symptoms include:
- Frequent urination as the kidneys are trying to expel excess sugar in the blood, resulting in dehydration which leads to extreme thirst.
- Increased hunger or unexpected weight loss because the body is unable to attain enough energy from food
- Slow healing cuts as high blood sugar levels can affect blood flow which can cause nerve damage.
- Fatigue as the body is unable to convert sugar into energy
- Irritable behaviour combined with other symptoms can be a means of concern
Diabetes and the NHS
Diabetes costs the NHS approximately £9.8 billion per year, an estimate of 10% of total expenditures. Hospital admissions of children and young people with diabetes presents a considerable burden on themselves, their families and the NHS. It is estimated that approximately 80% of these cases are potentially avoidable.
A report produced by the National Paediatric Diabetes Audit found that although the numbers of admissions didn’t significantly differ year to year, it highlighted differences in terms of socio-economic risk factors:
- Living in a deprived area increases the risk of hospital admissions which can be attributed to lack of education in the community about diabetic symptoms and the management of diabetes.
- Children below 5 years of age have a 35% increased risk of hospitalisation compared to those aged 5-9
- Females have a 33% increased risk of developing type 1 diabetes compared to males.
- Children with poor diabetes control have a twelve-fold increased risk of hospital admission
- Insulin pump users have a 27% increased risk of hospital admission compared to those who use insulin injections.
Figure A. Number of preventable paediatric diabetes admissions [3]
Prevention
There are campaigns in place to aid in the early diagnosis of type 1 diabetes which mainly focus on raising awareness of the signs and symptoms of diabetes. On this World Diabetes Day, it is important to know that it is not just simply the responsibility of the diabetic patient to prevent admission but the main responsibility lies with the diabetic teams that inform the families with children who are diagnosed with type 1 diabetes.
Paediatric diabetes teams should ensure that the families and the children receive structured education for self-management when diagnosed and throughout the illness. In doing so, the diabetic teams should implement blood ketone testing from diagnosis and utilise the nationally agreed hypoglycaemia management guidelines. It is also important that diabetic teams are fully aware of the patient characteristics associated with a greater risk of admission and that they use this knowledge to develop anti-admission strategies specifically tailored to the needs of each individual group.
Primary care practitioners should seek access to a specialist diabetic team who they can refer to when deciding if a patient requires admission to hospital. Furthermore, they should access blood glucose and ketone testing to identify patients at risk of diabetic ketoacidosis that require hospital admission.
How Randox can Help
Randox offer a range of assays to diagnosis and monitor diabetes and to monitor associated complications. Some of these tests are unique to Randox, including:
Fructosamine
The Randox fructosamine assay employs the enzymatic method which offers improved specificity and reliability compared to conventional NBT-based methods. The Randox enzymatic method does not suffer from non-specific interferences unlike other commercially available fructosamine assays.
D-3-Hydroxybutyrate (Ranbut)
The Randox D-3-Hydroxybutyrate (Ranbut) assay detects the most abundant and sensitive ketone in the body, D-3-Hydroxybutyrate. The Randox Ranbut assay is used for the diagnosis of ketosis, more specifically diabetic ketoacidosis. Other commercially available tests, such as the nitroprusside method, are less sensitive as they only detect acetone and acetoacetate, not D-3-Hydroxybutyrate.
Adiponectin
The Randox adiponectin assay is a biomarker in diabetes testing as adiponectin is a protein hormone responsible for regulating the metabolism of lipids and glucose and influences the body’s response to insulin. Adiponectin levels inversely correlates with abdominal visceral fat levels.
Want to know more?
Contact us or visit our Diabetes panel page to learn more.
Related Products
Randox Reagents
Resource Hub
References
[1] National Paediatric Diabetes Audit and Royal College of Paediatrics and Child Health, National Paediatric Diabetes Audit Report 2012-15: Part 2, 2017
[2] NHS, “Avoiding Complications” – Type 1 Diabetes, Available at: https://www.nhs.uk/conditions/type-1-diabetes/avoiding-complications/ [Accessed on 24th October 2018].
[3] “Potentially Preventable Pediatric Hospital Inpatient Stays for Asthma and Diabetes, 2003-2012”, www.hcup-us.ahrq.gov, 2015. [Online] Available: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb192-Pediatric-Preventable-Hospitalizations-Asthma-Diabetes.jsp [Accessed 08-Nov-18]